{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:06:52Z","timestamp":1784581612425,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005088","name":"Beijing Municipal Health Commission","doi-asserted-by":"publisher","award":["2022-2-018"],"award-info":[{"award-number":["2022-2-018"]}],"id":[{"id":"10.13039\/501100005088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2025ZD01905200"],"award-info":[{"award-number":["2025ZD01905200"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["2208085MH260"],"award-info":[{"award-number":["2208085MH260"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["2022-1-007"],"award-info":[{"award-number":["2022-1-007"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016308","name":"Wuxi Health and Family Planning Commission","doi-asserted-by":"publisher","award":["BJ2023097"],"award-info":[{"award-number":["BJ2023097"]}],"id":[{"id":"10.13039\/501100016308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2306700"],"award-info":[{"award-number":["2023YFC2306700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC0872500"],"award-info":[{"award-number":["2023YFC0872500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFE0116000"],"award-info":[{"award-number":["2023YFE0116000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2308300"],"award-info":[{"award-number":["2023YFC2308300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lanwpc.2026.101835","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:13:17Z","timestamp":1773969197000},"page":"101835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Virologic, immunologic, and metabolic outcomes and mortality in people with HIV on bictegravir\/emtricitabine\/tenofovir alafenamide fumarate versus dolutegravir-based antiretroviral therapies: a retrospective multicenter cohort study in China"],"prefix":"10.1016","volume":"68","author":[{"given":"Xinsheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianguo","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-0108","authenticated-orcid":false,"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rugang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxia","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2518-9470","authenticated-orcid":false,"given":"Yanshan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7226-3787","authenticated-orcid":false,"given":"Guozhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5201-0452","authenticated-orcid":false,"given":"Xiaojun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2228-5401","authenticated-orcid":false,"given":"Song","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8161-7576","authenticated-orcid":false,"given":"Huachun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.lanwpc.2026.101835_bib1","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","year":"2017","journal-title":"Lancet HIV"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101835_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101835_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1916753","article-title":"Four decades of HIV\/AIDS - much accomplished, much to do","volume":"383","author":"Fauci","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101835_bib4","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/QAD.0b013e3283612419","article-title":"Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study","volume":"27","author":"Stellbrink","year":"2013","journal-title":"AIDS"},{"issue":"19","key":"10.1016\/j.lanwpc.2026.101835_bib5","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101835_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/QAI.0b013e318289545c","article-title":"A randomized double-blind comparison of coformulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results","volume":"63","author":"Zolopa","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10167","key":"10.1016\/j.lanwpc.2026.101835_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101835_bib8","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1097\/QAD.0000000000002979","article-title":"Dolutegravir\/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV","volume":"35","author":"Rolle","year":"2021","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101835_bib9","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1038\/s41467-023-41051-w","article-title":"Associations of modern initial antiretroviral therapy regimens with all-cause mortality in people living with HIV in resource-limited settings: a retrospective multicenter cohort study in China","volume":"14","author":"Wu","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101835_bib10","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"issue":"10","key":"10.1016\/j.lanwpc.2026.101835_bib11","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV"},{"issue":"10107","key":"10.1016\/j.lanwpc.2026.101835_bib12","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lanwpc.2026.101835_bib13","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3018(24)00183-8","article-title":"Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration","volume":"11","author":"Pantazis","year":"2024","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101835_bib14","doi-asserted-by":"crossref","first-page":"e652","DOI":"10.1093\/cid\/ciac621","article-title":"Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with human immunodeficiency virus (HIV): a multicenter prospective cohort study","volume":"76","author":"Mart\u00ednez-Sanz","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.lanwpc.2026.101835_bib15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/cid\/ciaf466","article-title":"Impact of different integrase strand transfer inhibitors on body mass index among people with HIV who newly started antiretroviral therapy in Shenzhen, China: a real-world data analysis","volume":"82","author":"Zhang","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101835_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/dkae392","article-title":"Comparing the long-term effectiveness and safety of dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort","volume":"80","author":"Ciccullo","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.lanwpc.2026.101835_bib17","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/14787210.2023.2279719","article-title":"Comparison of dolutegravir+Lamivudine and bictegravir\/emtricitabine\/tenofovir alafenamide in antiretroviral therapy-na\u00efve patients infected with HIV: preliminary results from clinical practice","volume":"22","author":"Gan","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101835_bib18","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S2352-3018(22)00046-7","article-title":"Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study","volume":"9","author":"Trickey","year":"2022","journal-title":"Lancet HIV"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101835_bib19","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/cid\/cix199","article-title":"Incident AIDS or death after initiation of human immunodeficiency virus treatment regimens including raltegravir or efavirenz among adults in the United States","volume":"64","author":"Cole","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101835_bib20","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cir626","article-title":"Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study","volume":"53","author":"Hasse","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101835_bib21","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/cid\/cir627","article-title":"Premature age-related comorbidities among HIV-infected persons compared with the general population","volume":"53","author":"Guaraldi","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanwpc.2026.101835_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101613","article-title":"Incidence and mortality of non-AIDS-defining cancers among people living with HIV: a systematic review and meta-analysis","volume":"52","author":"Yuan","year":"2022","journal-title":"eClinicalMedicine"},{"issue":"9","key":"10.1016\/j.lanwpc.2026.101835_bib23","first-page":"893","article-title":"Chinese Center for Disease Control and Prevention, National Center for AIDS\/STD control and prevention. AIDS and STD epidemic situation in China in the second quarter of 2024","volume":"30","year":"2024","journal-title":"Chin J AIDS STD"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101835_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40249-023-01119-7","article-title":"Immediate and long-term outcomes after treat-all among people living with HIV in China: an interrupted time series analysis","volume":"12","author":"Wu","year":"2023","journal-title":"Infect Dis Poverty"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101835_bib25","first-page":"1106","article-title":"[Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2021 edition)]","volume":"60","year":"2021","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101835_bib26","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s15010-021-01668-9","article-title":"Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020)","volume":"49","author":"Yang","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.lanwpc.2026.101835_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.975397","article-title":"Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Baoding, Hebei province, China","volume":"13","author":"Fan","year":"2022","journal-title":"Front Genet"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101835_bib28","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1473-3099(11)70097-4","article-title":"Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study","volume":"11","author":"Zhang","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101835_bib29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/ije\/dyp233","article-title":"Cohort profile: the Chinese national free antiretroviral treatment cohort","volume":"39","author":"Ma","year":"2010","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10.1016\/j.lanwpc.2026.101835_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.lanwpc.2026.101835_bib31","first-page":"5","article-title":"Statistical methods in cancer research. Volume I - the analysis of case-control studies","volume":"32","author":"Breslow","year":"1980","journal-title":"IARC Sci Publ"},{"issue":"10","key":"10.1016\/j.lanwpc.2026.101835_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101835_bib33","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(21)00242-3","article-title":"Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial nested in the HPTN 071 (PopART) trial","volume":"9","author":"Limbada","year":"2021","journal-title":"Lancet HIV"},{"issue":"17","key":"10.1016\/j.lanwpc.2026.101835_bib34","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1097\/QAD.0000000000000012","article-title":"Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa","volume":"27","author":"Amornkul","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.lanwpc.2026.101835_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100600","article-title":"Temporal trends of early mortality and its risk factors in HIV-infected adults initiating antiretroviral therapy in Uganda","volume":"28","author":"Ssempijja","year":"2020","journal-title":"eClinicalMedicine"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101835_bib36","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101835_bib37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101835_bib38","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jac\/dkad102","article-title":"Effectiveness and tolerability of dolutegravir\/lamivudine for the treatment of HIV-1 infection in clinical practice","volume":"78","author":"Su\u00e1rez-Garc\u00eda","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanwpc.2026.101835_bib39","series-title":"Biktarvy [package insert]","year":"2018"},{"key":"10.1016\/j.lanwpc.2026.101835_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101835_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12981-025-00788-8","article-title":"High HIV viral suppression among adults receiving WHO-recommended first-line dolutegravir-based antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis of programmatic evidence","volume":"22","author":"Gir\u00f3n-Callejas","year":"2025","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.lanwpc.2026.101835_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fviro.2025.1653276","article-title":"Effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide fumarate for people with ultra-high viral load of HIV-1: a retrospective real-world cohort study","volume":"5","author":"He","year":"2025","journal-title":"Front Virol"},{"key":"10.1016\/j.lanwpc.2026.101835_bib43","doi-asserted-by":"crossref","DOI":"10.31744\/einstein_journal\/2023AO0156","article-title":"Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens","volume":"21","author":"Silva","year":"2023","journal-title":"Einstein (Sao Paulo)"},{"issue":"6","key":"10.1016\/j.lanwpc.2026.101835_bib44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1468-1293.2010.00890.x","article-title":"Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort","volume":"12","author":"Cescon","year":"2011","journal-title":"HIV Med"},{"issue":"21","key":"10.1016\/j.lanwpc.2026.101835_bib45","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1182\/blood-2010-12-322453","article-title":"Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection","volume":"117","author":"Corbeau","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101835_bib46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00002030-200202150-00007","article-title":"The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy","volume":"16","author":"Kaufmann","year":"2002","journal-title":"AIDS"},{"issue":"13","key":"10.1016\/j.lanwpc.2026.101835_bib47","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1097\/00002030-200309050-00009","article-title":"Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy","volume":"17","author":"Hunt","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.lanwpc.2026.101835_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101471","article-title":"Residual immune dysfunction under antiretroviral therapy","volume":"51","author":"Cai","year":"2021","journal-title":"Semin Immunol"},{"key":"10.1016\/j.lanwpc.2026.101835_bib49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2015.03.002","article-title":"Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort","volume":"117","author":"Pacheco","year":"2015","journal-title":"Antiviral Res"},{"issue":"22","key":"10.1016\/j.lanwpc.2026.101835_bib50","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lanwpc.2026.101835_bib51","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/cid\/civ296","article-title":"The lipid-lowering effect of tenofovir\/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial","volume":"61","author":"Santos","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101835_bib52","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","article-title":"A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206","volume":"24","author":"Tungsiripat","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.lanwpc.2026.101835_bib53","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/QAD.0000000000004085","article-title":"Body weight changes in people living with HIV starting dolutegravir versus efavirenz-based regimens in a large cohort in rural Tanzania","volume":"39","author":"Weisser","year":"2025","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.lanwpc.2026.101835_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26371","article-title":"Impact of switching to a dolutegravir-based regimen on body weight changes: insights from West African adult HIV cohorts","volume":"27","author":"Tiendrebeogo","year":"2024","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101835_bib55","article-title":"Weight gain in HIV adults receiving antiretroviral treatment: current knowledge and future perspectives","volume":"14","author":"Markakis","year":"2024","journal-title":"Life (Basel)"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101835_bib56","doi-asserted-by":"crossref","first-page":"e2234","DOI":"10.1093\/cid\/ciaa1403","article-title":"Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada","volume":"73","author":"Rebeiro","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101835_bib57","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"Bourgi","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101835_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108259","article-title":"Longitudinal trajectories of weight changes among people living with HIV on antiretroviral therapy: a group-based study","volume":"26","author":"Wu","year":"2023","journal-title":"iScience"},{"issue":"8","key":"10.1016\/j.lanwpc.2026.101835_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/v14081677","article-title":"Changes in body mass index after initiation of antiretroviral treatment: differences by class of core drug","volume":"14","author":"Pantazis","year":"2022","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.lanwpc.2026.101835_bib60","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(22)00094-7","article-title":"Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium","volume":"9","author":"Neesgaard","year":"2022","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101835_bib61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","article-title":"Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study","volume":"43","author":"Palella","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.lanwpc.2026.101835_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059768","article-title":"Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era","volume":"8","author":"Grinsztejn","year":"2013","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"10.1016\/j.lanwpc.2026.101835_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hiv.12833","article-title":"The potential role of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV","volume":"21","author":"Stellbrink","year":"2020","journal-title":"HIV Med"},{"issue":"1","key":"10.1016\/j.lanwpc.2026.101835_bib64","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12981-024-00681-w","article-title":"Effectiveness of dolutegravir-based regimens compared to raltegravir-, elvitegravir-, bictegravir, and darunavir-based regimens among older adults with HIV in the Veterans Aging Cohort Study (VACS)","volume":"21","author":"Yan","year":"2024","journal-title":"AIDS Res Ther"},{"issue":"11","key":"10.1016\/j.lanwpc.2026.101835_bib65","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1016\/S2352-3018(23)00228-X","article-title":"HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis","volume":"10","author":"Loosli","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.lanwpc.2026.101835_bib66","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2147\/DDDT.S406255","article-title":"Genetic diversity and characteristics of drug resistance among treatment-naive people living with HIV in Xi'an, China","volume":"17","author":"Xia","year":"2023","journal-title":"Drug Des Devel Ther"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606526000398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606526000398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:31:39Z","timestamp":1784579499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606526000398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":66,"alternative-id":["S2666606526000398"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101835","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virologic, immunologic, and metabolic outcomes and mortality in people with HIV on bictegravir\/emtricitabine\/tenofovir alafenamide fumarate versus dolutegravir-based antiretroviral therapies: a retrospective multicenter cohort study in China","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2026.101835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101835"}}